secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-130498
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx receives FDA IND clearance for UX016 in GNE myopathy; Phase 1/2 to start H2 2026
--------------------------------------------------------------------------------

- FDA cleared IND for UX016, a prodrug of sialic acid for GNE myopathy, a rare inherited neuromuscular disorder.
- UX016 is a small molecule prodrug designed to enhance sialic acid delivery to muscle cells.
- Phase 1/2 study planned for H2 2026, enrolling ~24 adults aged 18–55 in the US; externally funded by a patient group.
- Study will evaluate safety, pharmacokinetics, and efficacy including muscle strength and functional measures through 48 weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526130498/0001193125-26-130498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526130498/rare-20260330.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-130498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer